Iovance Biotherapeutics Inc (IOVA) Position Boosted by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its position in shares of Iovance Biotherapeutics Inc (NASDAQ:IOVA) by 34.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 477,565 shares of the biotechnology company’s stock after acquiring an additional 122,731 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.39% of Iovance Biotherapeutics worth $4,227,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Wells Fargo & Company MN boosted its stake in shares of Iovance Biotherapeutics by 91.4% in the third quarter. Wells Fargo & Company MN now owns 158,458 shares of the biotechnology company’s stock valued at $1,783,000 after purchasing an additional 75,671 shares during the period. BlackRock Inc. increased its holdings in shares of Iovance Biotherapeutics by 5.7% in the 3rd quarter. BlackRock Inc. now owns 6,653,978 shares of the biotechnology company’s stock valued at $74,858,000 after acquiring an additional 357,287 shares during the period. Dimensional Fund Advisors LP acquired a new position in shares of Iovance Biotherapeutics in the 3rd quarter valued at $344,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Iovance Biotherapeutics in the 3rd quarter valued at $601,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Iovance Biotherapeutics in the 3rd quarter valued at $282,000. Institutional investors own 96.90% of the company’s stock.

A number of equities analysts recently weighed in on the stock. Piper Jaffray Companies started coverage on shares of Iovance Biotherapeutics in a research report on Monday, April 29th. They issued an “overweight” rating and a $20.00 price objective on the stock. Chardan Capital reissued a “buy” rating on shares of Iovance Biotherapeutics in a research note on Tuesday, April 23rd. B. Riley reaffirmed a “buy” rating on shares of Iovance Biotherapeutics in a research note on Friday, April 5th. BidaskClub raised shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, April 4th. Finally, ValuEngine raised shares of Iovance Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, April 4th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $22.50.

IOVA traded down $0.10 on Thursday, reaching $10.73. 569,900 shares of the company’s stock were exchanged, compared to its average volume of 1,012,118. The company has a market cap of $1.34 billion, a PE ratio of -8.34 and a beta of 1.97. Iovance Biotherapeutics Inc has a twelve month low of $7.26 and a twelve month high of $18.25.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.01). On average, analysts expect that Iovance Biotherapeutics Inc will post -1.18 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Iovance Biotherapeutics Inc (IOVA) Position Boosted by Bank of New York Mellon Corp” was published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/05/09/bank-of-new-york-mellon-corp-has-4-23-million-stake-in-iovance-biotherapeutics-inc-iova.html.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Recommended Story: Investing strategies using the yield curve

Institutional Ownership by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.